Characterizing inpatient hospitalizations for hidradenitis suppurativa in the United States - 09/01/20
Doi : 10.1016/j.jaad.2019.09.019
Laura Anzaldi, MD a, Jamilah A. Perkins, MHS b, ⁎ 
, Angel S. Byrd, MD, PhD c, Hadi Kharrazi, MD, PhD d, Ginette A. Okoye, MD c
, Angel S. Byrd, MD, PhD c, Hadi Kharrazi, MD, PhD d, Ginette A. Okoye, MD c a Johns Hopkins University School of Medicine, Baltimore, Maryland
b Meharry Medical College, Nashville, Tennessee
c Department of Dermatology, Howard University College of Medicine, Washington, DC
d Johns Hopkins Bloomberg School of Public Health, Center for Population Health Information Technology, Baltimore, Maryland
∗Correspondence to: Jamilah A. Perkins, MHS, 2000 E Monument, Baltimore, MD 212052000 E MonumentBaltimoreMD21205
| A portion of these data were presented as a poster presentation at the 2017 Symposium for Hidradenitis Suppurativa Advances, Detroit, Michigan, November 4-5, 2017. |
|
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 82 - N° 2
P. 510-513 - février 2020 Retour au numéro
Article précédent
- Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review
- Leo L. Wang, Robert G. Micheletti
- Impact of dermatology and teledermatology consultations for patients admitted with cellulitis: A pilot study
- Preeta Gupta, Starling Tolliver, Myron Zhang, Eric Schumacher, Benjamin H. Kaffenberger
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?